Abstract: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare type of B-cell lymphoma with good prognosis and distinct clinicopathologic features. The hallmark histological feature is the presence of malignant lymphocyte predominant (LP) cells embedded within nodules predominantly composed of small B-lymphocytes. Immunoarchitectural variations from these classic nodules could occur. The clinical and pathological significance of NLPHL with variant patterns is, however, uncertain and controversial. Some oncologists and pathologists consider variant atypical nodules to represent a simple localized overgrowth of the LP cells without significant pathological or clinical implications. Other oncologists, however, suggest that they might represent a different biological behavior in the form of intranodal progression with early transformation into large B-cell lymphoma. Therefore, NLPHLs with variant atypical patterns represent a more aggressive clinical course and an indicator of a higher risk of recurrence that warrants a more aggressive treatment even in the early stages.
INTRODUCTION

Nodular
lymphocyte predominant Hodgkin lymphoma (NLPHL) constitutes 3-5% of Hodgkin lymphoma (HL) [1, 2] . The hallmark histological feature is the presence of malignant CD20 positive lymphocyte predominant (LP) cells embedded within nodules composed of small B-lymphocytes [1] . NLPHL is currently considered a B-cell lymphoma of germinalcenter origin with a good overall prognosis [1, 3, 4] . However, recurrence could occur and transformation into large B-cell non-Hodgkin lymphoma (NHL) has been reported with an incidence of 2-3% [1, 5, 6] . Variations from the usual classic nodules of NLPHL can occur, the prevalence and significance of which is, however, not yet resolved [2, 7] . We performed a retrospective review study to investigate the prevalence and importance of aberrant nodules in NLPHL.
MATERIALS AND METHODS
A computer-based search was used to retrieve all cases of NLPHL that were diagnosed in our institution over the past five years. For each case, sections of 4-6 μm thickness were stained with routine hematoxylin and eosin (H&E) stain and one H&E stained slide for *Address corresponding to this author at the Pathology section, Rashid hospital, Oud Metha Road, Dubai, United Arab Emirates; Tel: 00971 4 219 5437; Fax: 00971 4 271 9340; E-mail: badraah009@yahoo.com each block was prepared. The retrieved cases were divided into NLPHL with classic conventional nodules and NLPHL with any aberrant variant nodules. The histologic features were compared for each case. We compared the size, shape and location of the nodules as well as their demarcation from the surrounding lymphoid tissue. We also compared the nature of the neoplastic cells within the nodules along with the lymphocytic background and the pattern of the epithelioid histiocytes within the nodules.
Based on the initial microscopic examination, immunohistochemistry (IHC) panel was conducted with the following available markers: CD45 (LCA), CD20, CD79a, CD30, CD15, CD3, CD10, CD23, CD21, bcl2, bcl6, EMA (Epithelial Membrane Antigen), EBV-EBER (Epstein Barr Virus) and Ki67 (Dako, Glostrup, Denmark). IHC study was performed on the formalinfixed, paraffin-embedded blocks with the above primary antibodies using a standard automated streptavidinbiotin-peroxidase detection system (Dako, Glostrup, Denmark) with microwave antigen-retrieval. Positive and negative controls were run in parallel for every stain.
For each case relevant clinical features were also collected. They included the age, gender, anatomical location and size of the involved lymph nodes, the clinical symptoms along with the disease stage, the received therapy and follow up and survival data. The medical file for each patient was retrieved and reviewed thoroughly to collect the above clinical data for each case. The retrieved cases were divided into three groups and the histological and clinical features of the three groups were tabulated for comparison in Table 1 .
RESULTS
We retrieved seven cases of NLPHL. Four cases showed the classic nodules of NLPHL with the typical immunoarchitectural pattern of scattered CD20 positive LP cells and a background of small CD20 positive lymphocytes (Figure 1 ).
Three cases (43%) showed, in addition to the classic nodules of NLPHL, foci of enlarged nodules with different immunoarchitectural patterns ( Table 1) . One case showed frequent nodules composed of sheets of large pleomorphic neoplastic lymphoid cells (Figure 2) . CD45 (LCA) and CD20 stained the large cells and the background small lymphocytes (Figure 2 ). CD79a and bcl6 stained the large cells. CD30, CD15, bcl2 and EBV were negative. CD10 stained few large cells in these nodules. CD57 showed nesting pattern around the large cells in the classic nodules and in the atypical nodules. Ki67 proliferation index was low (3%) in the classic nodules and was increased (40%) in the atypical nodules (Figure 2 ). CD21 and CD23 were negative in the atypical nodules suggesting complete absence of the follicular dendritic cells (FDCs).
The other two cases showed foci of well-defined expanded nodules surrounded by collagen bundles (Figure 3) . These nodules showed frequent large lymphoid cells within a background of small Tlymphocytes (Figure 3) . The large lymphoid cells were positive for LCA, CD20, CD79a, bcl6, EMA and CD30. They were negative for CD15, ALK, CD10, bcl2 and EBV. CD23 and CD21 were absent in these aberrant nodules. CD3 showed a dominant background of small T-lymphocytes in these nodules (Figure 3 ) in contrast to the B-lymphocytes dominant background in the adjacent classic nodules (Figure 1 ). Ki67 proliferation index was 10% in these atypical nodules (Figure 3) .
We reported the three cases as NLPHL with variable histological features. One case had diffuse large B-cell lymphoma-like nodules (DLBCL) and received R-CHOP (Rituximab, Cyclophosphamide, Adriamycin, Vincristine and Prednisone) treatment. The other two cases had T-cell rich B-cell lymphoma-like nodules (TCRBCL). One received ABVD (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) chemotherapy and the other had combined radiotherapy (RT) and ABVD. Three patients with classic NLPHL received RT, and the fourth patient received ABVD ( Table 1 ). All patients presented with early-localized disease. All patients were disease free and alive after a follow up period that ranged between 2.5 and 7 years. We did not find major clinical or prognostic differences between the three groups ( Table 1 ). 
DISCUSSION
The exact etiology and pathogenesis of NLPHL are still controversial. NLPHL is considered a germinalcenter derived B-cell lymphoma [2, 3, 5] . NLPHL is considered to be more linked to B-cell NHL rather than being a variant of HL [2, 3, 5] . The neoplastic LP cells have been demonstrated to originate from the germinal-center B-cells [3, 5] . Several hypotheses suggest a link between NLPHL and progressive transformation of germinal centers (PTGC) [8] . PTGC is considered a precursor lesion for NLPHL [8] . Documented cases of concurrent or subsequent transformation of NLPHL into large B-cell lymphoma were reported more in NLPHL than in HL, with an overall incidence of 2-3% [6] . In contrast to classic HL, EBV has no role in the pathogenesis of NLPHL [3, 5] .
Variations from the classic nodules of NLPHL in the form of nodules with different immunoarchitectural patterns do occur, albeit rare [2, 4, 7] . Fan et al. [7] subclassified the nodules of NLPHL into six categories on the basis of immunoarchitectural patterns as follows: 1) classic (small B-cell rich) nodular; 2) serpinginous, interconnected nodular; 3) nodular with extranodular lymphocytic and histiocytic (L&H) cells; 4) (small T-cell rich) nodular; 5) diffuse (T-Cell Rich B-Cell Lymphoma-like (TCRBCL-like) and 6) diffuse (Large BCell Lymphoma-like (DLBCL-like). The TCRBCL-like and the DLBCL-like atypical nodules could suggest early intranodal transformation of NLPHL into highergrade large B-cell lymphoma [2] . They may explain the progression of 5% of NLPHL cases into large B-cell lymphoma [2, 6, 7] . Some suggested a sequence of events that explain the occurrence of these atypical nodules and their progression into large B-cell lymphoma. Atypical follicular hyperplasia (PTGC) progresses into classic NLPHL nodules which develop into either TCRBCL-like nodules or DLBCL-like nodules which ultimately transform into DLBCL [3, 5, 8] . NLPHL is not a static disease process, but rather a dynamic lymphoid malignancy with a tendency for concurrent or subsequent transformation into large B-cell lymphoma [3, 5, 6, 8] .
The optimal treatment for NLPHL is also controversial. Early stage classic NLPHL is usually a localized disease with excellent prognosis, and patients either receive RT alone or combined RT and chemotherapy [1, 6] . For a higher stage disease, a more aggressive chemotherapy approach is agreed by most oncologists [2, 9] . For the early stage NLPHL, but with variant pathologic patterns, some oncologists advocate a more aggressive chemotherapy approach.
They recommend R-CHOP regimen, on the basis that these cases are at a higher risk of transformation into a high grade large B-cell lymphoma or are more likely to recur and relapse in the future [2, 4, 9] .
In our study, we did not find significant clinical or prognostic differences between the classic NLPHL cases and the other NLPHL cases with the atypical nodules. However, our study is limited because it is a small case series. Therefore the clinical or prognostic importance of the variant patterns cannot be drawn from the small number of the cases studied. We recommend a larger scale study to investigate the prognostic and therapeutic implications of these atypical nodules in NLPHL.
In conclusion, variant nodules in NLPHL are not uncommon and might present a diagnostic challenge for the pathologists. They could lead to misinterpretation of NLPHL as a high grade lymphoma with unnecessary more aggressive treatment. The clinical and prognostic significance of these atypical nodules in NLPHL as well as the best acceptable management of these cases are, however, controversial and uncertain. This needs to be validated by a larger scale study.
